Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus ...
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary ...
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, in Advanced NSCLC ...
SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...
1. Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to phase II clinical research in idiopathic pulmonary fibrosis. News release. Boehringer-Ingelheim. January 13, 2026. Accessed ...
IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease ...
GlobalData on MSN
AbCellera begins Phase II ABCL635 trial for menopause-related VMS
The Phase II segment is a randomised, double-blind, placebo-controlled study assessing ABCL635 efficacy in 80 postmenopausal ...
Medical research shapes healthcare every day, but not all studies are created equal. Knowing the differences can help you feel more confident reading health information online and understanding what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results